Evidence map›Paper›PMID 39313767›Full record

ArticleInternational journal of immunopathology and pharmacology

Umbelliprenin improved anti-proliferative effects of ionizing radiation on adult T-cell leukemia/lymphoma cells via interaction with CDK6; an

Keyhan Ebrahimi, Ramin Bagheri, Hamid Gholamhosseinian, Mohammad Reza Keramati, Houshang Rafatpanah, Mehrdad Iranshahi, Fatemeh B Rassouli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Keyhan EbrahimiCancer Molecular Pathology Research Center, Department of Hematology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ramin BagheriCancer Molecular Pathology Research Center, Department of Hematology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid GholamhosseinianDepartment of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza KeramatiCancer Molecular Pathology Research Center, Department of Hematology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Houshang RafatpanahImmunology Research Center, Inflammation and inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehrdad IranshahiBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh B RassouliNovel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.ORCID 0000-0003-1889-0964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy with poor survival rates. The efficacy of radiotherapy in ATL needs enhancement with radiosensitizing agents. This study investigated whether umbelliprenin (UMB) could improve the therapeutic effects of ionizing radiation (IR) in ATL cells. UMB, a naturally occurring prenylated coumarin, exhibits anticancer properties and has shown synergistic effects when combined with chemotherapeutic drugs. Despite this promising profile, there is a notable lack of research on its potential combinatorial effects with IR, particularly for ATL treatment. UMB was extracted from

Indexed as

Cell ProliferationCyclin-Dependent Kinase 6Leukemia-Lymphoma, Adult T-CellUmbelliferonesApoptosisCell Line, TumorComputer SimulationFerulaHumansMolecular Docking SimulationProtein Interaction MapsRadiation, IonizingRadiation-Sensitizing AgentsCDK6 protein, humanCyclin-Dependent Kinase 6Radiation-Sensitizing AgentsUmbelliferonesumbellipreninadult T-cell leukemia/lymphomaCDK6combinatorial treatmentionizing radiationumbelliprenin

Identifiers

PMID39313767
PMCPMC11437583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.